Iroko Pharmaceuticals Release: SoluMatrix® Meloxicam Demonstrates Significant Efficacy At 30 Percent Lower Doses In The Treatment Of Osteoarthritis
6/12/2014 9:40:19 AM
PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix® meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo1. These data are being presented at the 2014 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Paris, France.
Help employers find you! Check out all the jobs and post your resume.
comments powered by